Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1994-1-24
pubmed:abstractText
To analyse the immunological mechanism of hepatocellular injury in hepatitis B virus (HBV) infection, the immunoreactivity of HBV-encoded antigens as a target for cytotoxic T lymphocyte (CTL) response was examined using recombinant vaccinia virus (RVV) expressing surface protein (S), precore/core protein (PC), and core protein (C) of HBV. C3H/He mice (H-2k) were inoculated with each RVV. Their spleen cells were then harvested and stimulated in vitro with the histocompatible transfectant, which stably expressed hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antigen (HBcAg), and used as effectors. As the targets, L cells (H-2k) infected with individual RVV were used. Cytotoxic test was performed with various combinations and ratios of effectors and targets. The reactivity of PC-primed effectors against PC-expressing targets was greatest with 71.4% specific lysis on average at an effector/target ratio of 12.5:1 among all the combinations. C-primed effectors against C-expressing target also revealed rather high cytotoxicity (specific lysis, 40.6% at an E/T ratio of 12.5:1). Furthermore, PC-primed and C-primed effectors showed a cross-reactivity to the targets expressing other nucleocapsid antigen, respectively. S-primed effectors showed less lytic activity against S-expressing targets (specific lysis, 18.4% at an E/T ratio of 12.5:1). The CTL responses were blocked by anti-CD8 and anti-major histocompatibility complex (MHC) class I antibodies, but not by anti-CD4 or anti-MHC class II. These findings suggest that endogenously synthesized nucleocapsid antigen, especially PC, is a dominant target for the MHC class I-restricted CTL in H-2k mice and that this system may work as an efficient model to study immunopathogenesis of HBV infection.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-1660137, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-1691527, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-1720813, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-1727493, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-1752941, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2313098, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2411422, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2437457, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2439103, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2442285, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2443855, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2448497, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2457647, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2469730, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2477450, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-2671579, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-3491325, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-3494760, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-3498568, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-3783127, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-6189903, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-6321770, http://linkedlifedata.com/resource/pubmed/commentcorrection/8262560-6982941
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0019-2805
pubmed:author
pubmed:issnType
Print
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
313-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Relative immunogenicity of hepatitis B virus-encoded antigens as targets for cytotoxic T-cell response.
pubmed:affiliation
Third Department of Internal Medicine, Nagoya University of Medicine, Japan.
pubmed:publicationType
Journal Article